The Global Health Body Raises Concern Over Acute Scarcity of Obesity Injections
Fewer than a tenth of patients eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it publishes its first guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidance affirms that obesity is a chronic disease that can be addressed with holistic and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to broad availability to the jabs that can aid individuals in losing substantial weight, notes the organization.
Skinny Jab Shortage
Even under the current best projected scenario, the manufacturing of such drugs might only reach approximately 100 million people – under 10% of eligible patients, according to the WHO.
The guideline urges nations and manufacturers to expand access, by strategies such as patent sharing.
A patent on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Injections Operate
These medications imitate a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so people eat less.
Patients typically start to lose weight within a few weeks of starting on the regular doses.
Studies suggests users may regain a significant portion within a year of discontinuing the drug, when their normal hunger return.
Being overweight or obese raises your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Excess weight concerns individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.
